Assertio Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $32,182 | $29,204 | $31,126 | $32,448 |
Gross Profit | 20,571 | 21,654 | 22,237 | 15,540 |
EBITDA | -3,388 | 4,595 | 3,944 | 2,114 |
EBIT | -10,099 | -2,116 | -2,767 | -3,617 |
Net Income | -10,476 | -2,921 | -3,674 | -4,510 |
Net Change In Cash | 32,182 | 29,204 | 31,126 | 32,448 |
Free Cash Flow | 11,548 | -35 | 7,387 | 7,508 |
Cash | 50,588 | 37,981 | 44,735 | 80,743 |
Basic Shares | 95,509 | 95,352 | 95,240 | 94,980 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $124,961 | $152,069 | $156,234 | $111,014 |
Gross Profit | 85,734 | 125,049 | 137,486 | 95,182 |
EBITDA | -24,476 | -222,447 | 72,535 | 38,781 |
EBIT | -250,676 | 39,127 | 9,667 | |
Net Income | -21,477 | -331,942 | 109,625 | -1,281 |
Net Change In Cash | 124,961 | 152,069 | 156,234 | 111,014 |
Free Cash Flow | 26,408 | 48,976 | 78,324 | 5,470 |
Cash | 50,588 | 73,441 | 64,941 | 36,810 |
Basic Shares | 95,271 | 71,031 | 54,669 | 43,169 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.03 |
2024-09-30 | -$0.03 |
2024-06-30 | -$0.04 |
2024-03-31 | -$0.05 |
